A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Academic Article uri icon

Overview

abstract

  • Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.

publication date

  • October 15, 2011

Research

keywords

  • Neoplasms
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins
  • Vascular Endothelial Growth Factor A

Identity

PubMed Central ID

  • PMC3432791

Scopus Document Identifier

  • 84867847536

Digital Object Identifier (DOI)

  • 10.1007/s10637-011-9753-y

PubMed ID

  • 22002018

Additional Document Info

volume

  • 30

issue

  • 5